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Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S90with 4e6 (HR 1.59; 95% CI 1.27e2.00; P < 0.001). HCT from a
female donor to a male recipient (FDMR) and disease status
were signiﬁcant risk factors among themEBMT variables. We
developed a new risk score (ATL-HCT-PI) based on known
risk factors (PS, human leukocyte antigen mismatch, ABO
mismatch), age (50, 51e62, 63 years), arrhythmia, dia-
betes mellitus, cardiovascular comorbidities, infection, he-
patic comorbidities, renal comorbidities, FDMR, and disease
status (CR vs. non-CR). ATL-HCT-PI scores were collapsed into
three risk groups: ATL-HCT-PI 0e7 (n¼ 285), 8e14 (n¼ 237),
and 15 (n ¼ 92), which statistically predicted 3-year OS
(48.3%, 29.2%, and 5.5%, respectively) (Figure). The better
predictive performance of ATL-HCT-PI for OS was
conﬁrmed using c-statistics (c-statistics: ATL-HCT-PI ¼
0.705, HCT-CI ¼ 0.592, and mEBMT ¼ 0.601).
Conclusions: ThenewlydevelopedATL-HCT-PI canbeauseful
tool for predicting mortality in HCT for patients with ATL.PEDIATRIC DISORDERS87
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Background: Patients with sickle cell disease (SCD) have an
average life expectancy of 39 years. The only known curative
therapy is allogeneic stem cell transplantation (AlloSCT) from
an HLA-matched donor (Talano/Cairo EJH, 2014). We have
demonstrated 100% EFS and absence of sickle cell symptoms
following reduced intensity conditioningandmatched sibling
bone marrow or cord blood AlloSCT (Bhatia/Cairo et al, BMT,
2014). However, matched sibling donors (MSD) and matched
unrelated donors (MUD) are limited and unrelated cord blood
transplant results are poor (Radhakrishnan K/Cairo et al.,
BBMT 2013, Kamani et al., BBMT, 2012). FHI TCD stem cell
transplantationhasbeenusedwithhigh engraftment and low
aGVHD rates in high risk thalassemia patients and similar
resultswere reportedwith bothmalignant andnonmalignant
diseases (Sodani et al., Blood, 2010). Using a similar approach,
we reported the success of CD34 selectionwith T-cell addback
following MUD transplant in children (Geyer/Cairo BJH,
2012). FHI TCD AlloSCT could expand the donor pool and
improve outcomes for patients with high risk SCD.
Objective: To determine the safety and feasibility of FHI TCD
AlloSCT with T-cell addback in patients with high-risk SCD.
Methods: A multicenter consortium was developed to
investigate this approach (Fig. 1). Patients (2-<21 yrs) without
an 8/8 HLA MSD or MUD and who have 1 high-risk
SCD features are eligible. Patients receive hydroxyurea
(60mg/kg/d) and azathioprine (3mg/kg/d) day -59eday -11,
ﬂudarabine (30mg/m2/d x5d), busulfan (3.2mg/kg/d x4d),
thiotepa (10mg/kg x1d), cyclophosphamide (50mg/kg x4d),Haploidentical AlloSCT Sickle Cell Disease Consortium.
Figure 2. Patient Outcomes.
Table
Leiden Utrecht Total
Number of patients (n) 142 109 251
Male sex [n (%)] 96 (68) 61 (56) 157 (63)
Age (years) 6á2 (0á4-19) 5á9 (0á2-23) 6á2 (0á2-23)
Cumulative Thymoglobulin
dose [n (%)]
<9 mg/kg 4 (3) 5 (5) 9 (4)
9-11 mg/kg 136 (96) 97 (89) 233 (92)
>11 mg/kg 2 (1) 7 (6) 9 (4)
Diagnosis [n (%)]
Malignancy 69 (49) 47 (43) 116 (46)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S91R-ATG (2mg/kg/d x4d), and TLI (500cGy) followed by FHI TCD
AlloSCT. We utilize the CliniMACS System (IND 14359) to
enrich for peripheral blood hematopoietic progenitor cells
with a target dose of 10 x 106 CD34+ cells/kg and 2 x 105
CD3+ T cells/kg added back as a ﬁnal CD3/kg concentration.
Results: Seven patients have received AlloSCTs from
maternal donors. Neutrophil engraftment has been rapid
(median 9d; range, 9-13d) and none has developed GVHD.
All patients have achieved94% whole blood chimerism and
CD71 (erythroid) chimerism (Fig. 2). Six evaluable patients
achieved full donor (95%) peripheral blood chimerism by
day 60, and 3 of 6 achieved full donor CD3 chimerism in
that time (Fig. 2). Absolute CD4 counts of 200/mm3 have
been achieved in all patients 270 days post-transplant.
There have been no serious bacterial infections and only 1
viral infection. Six of 7 patients are alive and free of disease
(day +24 to +710) with 1 death of VOD at day +59.
Early results indicate FHI TCD AlloSCT is feasible and well
tolerated inhigh-risk SCDpatients. A larger cohort is needed to
assess long-term safety and outcomes. (Supported by grants
from the FDA [5R01FD004090] and Otsuka and CliniMACS
supplies from Miltenyi Biotec) (IND#14359; NCT01461837;
http://www.sicklecelltransplantconsortium.org)Immune deﬁciency 23 (16) 28 (26) 51 (20)
Bone marrow failure 6 (4) 9 (8) 15 (6)
Benign disorders 44 (31) 25 (23) 69 (28)
Stem cell source [n (%)]
Bone marrow 89 (63) 29 (27) 118 (47)
Peripheral blood stem cells 30 (21) 12 (11) 42 (17)
Cordblood 23 (16) 68 (62) 91 (37)
Conditioning regimen
[n (%)]
Reduced intensity 0 (0) 6 (5) 6 (2)
Chemotherapy-based 103 (73) 88 (81) 191 (76)
TBI-based 39 (27) 15 (14) 54 (22)
Positive CMV status of
recipient [n (%)]
70 (49) 56 (51) 126 (50)
Positive CMV status of
donor [n (%)]
57 (40) 19 (17) 76 (30)
Follow up (weeks) 126 (3-427) 84 (1-382) 111 (1-427)
Shown as median (range)
unless otherwise
speciﬁed
Thymoglobulin exposure is a predictor for IR, GvHD and GF, and in sub-
groups for OS. IR is a predictor for OS and EFS. Individualized dosing of
Thymoglobulin targeting to optimal Thymoglobulin exposures may
improve the outcomes after (pediatric) HCT.88
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Leiden, NetherlandsThymoglobulin is introduced to the conditioning regimen in
hematopoietic cell transplantation (HCT) to prevent graft-
versus-host-disease (GvHD) and graft failure (GF). Side
effects of Thymoglobulin include delayed immune reconsti-
tution (IR) of donor T-cells. We determine the therapeutic
window by studying the relationship between Thymoglo-
bulin exposure and clinical outcome.
All ﬁrst HCT’s in pediatric patients between 2004-2012
receiving Thymoglobulin in the two Dutch pediatric HCT cen-
ters were included. Thymoglobulin exposure measures were
determined using a validated population pharmacokinetic
